Drugs / SPOT-mRNA01
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06567119 Comparator | Jan 2027 → Jan 2029 expected | skin atrophy | SIPO Biotechnology Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPOT-mRNA01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06567119 ↗ |
| Modality | Messenger RNA (mRNA) | “COL1A1 mRNA-loaded by EVs” NCT06567119 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT06567119 ↗ |
| Target | COL1A1 | “SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs)” NCT06567119 ↗ |